Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective-Reference-Cited by-同舟云学术

Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective

Published:2017-03 Issue:3 Volume:39 Page:567-580.e2
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Capri Stefano,Porta Camillo,Delea Thomas E.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference25 articles.

1. The epidemiology of renal cell carcinoma;Ljungberg;Eur Urol,2011

2. Renal-cell carcinoma;Cohen;N Engl J Med,2005

3. Estimates of the incidence and prevalence of renal cell carcinoma in Italy in 2002 and projections for the years 2007 and 2012;Bosetti;Tumori,2009

4. Epidemiologia e standard di cura attuale del carcinoma renale metastatico in Italia;Porta;Ital J Public Health,2011

5. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma;Keisner;Drugs,2011

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends of First-Line Targeted Therapy in Korean Patients With Metastatic Clear Cell Renal Cell Carcinoma: Sunitinib Versus Pazopanib, a Multicenter Study;The Korean Journal of Urological Oncology;2022-05-31

2. Cost-Effectiveness and Value of Information of Cabozantinib Treatment for Patients with Advanced Renal Cell Carcinoma After Failure of Prior Therapy in South Korea;Applied Health Economics and Health Policy;2021-03-02

3. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the ‘Pamerit’ study;Japanese Journal of Clinical Oncology;2020-11-20

4. An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy;Journal of Medical Economics;2020-11-05

5. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy;Journal of Medical Economics;2019-10-07